News | September 12, 2014

University of Wisconsin Carbone Cancer Center Becomes First in the World to Treat Patients With MRIdian’s Soft-Tissue-Tracking-Beam Control

ViewRay’s MRIdian system directly tracks tumor motion continuously during treatment

University of Wisconsin Carbone Cancer Center ViewRay MRIdian

September 12, 2014 — The MRIdian system from ViewRay is now being used to treat patients at the University of Wisconsin Carbone Cancer Center in Madison, Wis., the second clinical group in the world to treat patients with magnetic resonance imaging (MRI)-guided radiation therapy. With the treatment, the center also became the first clinic in the world to employ the soft-tissue tracking beam control feature of ViewRay’s MRIdian system.

The MRIdian system is the world’s first and only MRI-guided radiation therapy system. It provides continuous imaging during treatment so clinicians are able to see where the radiation dose is being delivered and adapt to changes and movement in the patient’s anatomy in real-time. The system tracks soft-tissues of the tumor directly, in fast planar images, then automatically compares the target to the plan and only allows treatment when the target is in range.

“We had a patient with very limited treatment options,” said Michael Bassetti, M.D., Ph.D., assistant professor of radiation oncology at the University of Wisconsin Carbone Cancer Center. “The size and location of this patient’s liver tumor combined with the large observable motion prevented the safe delivery of treatment with X-Ray based linac systems. With ViewRay’s MRIdian system, we were able to ensure the accuracy of the delivery by directly tracking tumor and normal soft-tissue movement during treatment.”

The first MRI-guided radiation therapy patient at Carbone Cancer Center was a liver cancer patient who was treated with the soft-tissue tracking beam control feature employing a 5 mm margin on a breath-hold scan acquired on the system.

“I am grateful UW-Madison can now provide this remarkable treatment approach to our patients,” said John Bayouth, Ph.D., professor and chief of physics at the University of Wisconsin Carbone Cancer Center. “MRIdian enabled us to meet demanding prescription goals through its ability to track the actual tumor and surrounding normal tissues in real-time. We minimized the radiation dose to the bowel and normal liver while verifying the dose delivered to the tumor during treatment delivery.  No longer do we have to assume what is happening inside the patient during treatment, now we are able to see changes and respond accordingly.”

“We are excited to be one of the first centers to use MRI-guided radiation therapy in clinical practice,” said Paul Harari, M.D., professor and chairman of the Ddpartment of human oncology at the University of Wisconsin School of Medicine and Public Health. “Continual MR image-guidance and control is unique to the MRIdian system with the potential to change the way clinicians treat cancer patients.”

For more information:

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init